Skip to main content
. 2023 Aug 11;9(8):e19073. doi: 10.1016/j.heliyon.2023.e19073

Table 3.

OCT analysis of culprit lesion.

Overall population (n = 249) Sex
p value
Male (n = 206) Female (n = 43)
Quantitative assessment
Distal reference lumen area, mm2 5.4 (4.1, 6.7) 5.5 (4.3, 6.8) 4.4 (3.6, 6.0) 0.003
Proximal reference lumen area, mm2 6.8 (5.7, 8.2) 6.9 (5.8, 8.2) 6.0 (4.4, 7.6) 0.010
Minimum lumen area, mm2 1.9 (1.4, 2.7) 1.9 (1.4, 2.8) 1.8 (1.3, 2.4) 0.322
Minimum lumen diameter, mm 1.5 (1.3, 1.8) 1.6 (1.3, 1.9) 1.5 (1.3, 1.7) 0.316
Minimum stent area, mm2 6.6 (5.4, 7.8) 6.6 (5.6, 7.9) 6.1 (4.7, 7.5) 0.073
Maximal NIH, % 0.7 (0.6, 0.8) 0.7 (0.6, 0.8) 0.7 (0.5, 0.8) 0.861
Mean intimal thickness 0.7 (0.5, 0.8) 0.7 (0.5, 0.8) 0.6 (0.4, 0.8) 0.285
Qualitative assessment, n (%)
Neointima characteristics at lesion
 Neoatherosclerosis 196 (78.7) 169 (82.0) 27 (62.8) 0.005
 Lipid neointima 187 (75.1) 160 (77.7) 27 (62.8) 0.040
 Lipid-rich plaque 159 (63.9) 139 (67.5) 20 (46.5) 0.009
 Maximum lipidic arc, 300.0 (205.8, 360.0) 305.5 (209.4, 360.0) 270.0 (150.0, 360.0) 0.315
 Calcified neointima 26 (10.4) 26 (12.6) 0 (0) 0.029
 Spotty calcification 15 (6.0) 15 (7.3) 0 (0) 0.141
Re-stenotic tissue structure 0.047
 Homogeneous 57 (22.9) 41 (19.9) 16 (37.2)
 Heterogeneous 142 (57.0) 123 (59.7) 19 (44.2)
 Layered 50 (20.1) 42 (20.4) 8 (18.6)
Distribution of ISR 0.401
 Focal 57 (22.9) 45 (21.8) 12 (27.9)
 Multifocal 95 (38.2) 77 (37.4) 18 (41.9)
 Diffuse 97 (38.9) 84 (40.8) 13 (30.2)
Restenotic tissue backscatter 0.042
 High 88 (35.3) 67 (32.5) 21 (48.8)
 Low 161 (64.7) 139 (67.5) 22 (51.2)
TCFA 81 (32.5) 77 (37.4) 4 (9.3) <0.001
Neointimal rupture 42 (16.9) 36 (17.5) 6 (14.0) 0.575
Thrombus 32 (12.9) 24 (11.7) 8 (18.6) 0.215
Neointimal macrophages 94 (37.8) 87 (42.2) 7 (16.3) 0.001
Microvessels 67 (26.9) 58 (28.2) 9 (20.9) 0.331
Underexpansion 7 (2.8) 5 (2.4) 2 (4.7) 0.768

Values are n (%) or median with first and third quartiles. ISR: in-stent restenosis; MLA: minimum lumen area; NIH: neointimal hyperplasia; TCFA:thin-cap fibrous atherosclerosis.